Girinimbine

Girinimbine is a carbazole alkaloid isolated from Murraya koenigii that induces cancer cell apoptosis through mitochondrial pathway activation—including cytochrome c release, caspase-3/9 activation, and Bcl-2 downregulation—while also inhibiting nitric oxide production and NF-κB translocation to exert anti-inflammatory effects. In preclinical assays, it demonstrated selective antiproliferative activity against A549 lung cancer cells (IC₅₀ ≈ 19.01 μM) and HT-29 colon cancer cells at up to 100 μg/mL without cytotoxicity to normal CCD-18Co fibroblasts, alongside 78.9% inhibition of nitric oxide production at 51 ± 3.81 μg/mL in LPS/IFN-γ-stimulated macrophages.

Origin & History

Girinimbine is a carbazole alkaloid naturally occurring in Murraya koenigii (curry leaf tree), a tropical and subtropical tree native to South and Southeast Asia, including India, Sri Lanka, and Malaysia. The compound is concentrated primarily in the leaves, stem bark, and roots of the plant, which thrives in well-drained soils under warm, humid conditions. Laboratory isolation requires solvent-based extraction followed by chromatographic purification, as girinimbine does not occur in commercially available concentrated form outside of research contexts.

Historical & Cultural Context

Murraya koenigii, the botanical source of girinimbine, has been used for millennia in Ayurvedic medicine (referenced in classical Sanskrit texts) and in traditional Southeast Asian healing systems for its digestive, antidiabetic, antimicrobial, and general tonic properties, with leaves commonly incorporated into Indian, Sri Lankan, and Malaysian cuisine as a flavoring agent. Healers in South India traditionally used fresh curry leaves to treat dysentery, diarrhea, nausea, and conditions associated with inflammation, though these therapeutic attributions applied to the whole plant material and not to any isolated constituent. Girinimbine as a discrete chemical entity was not identified or named in traditional knowledge systems; its isolation and structural characterization as a carbazole alkaloid represent modern phytochemical discoveries enabled by 20th-century analytical chemistry techniques. The cultural significance of curry leaf as a culinary and medicinal staple across South and Southeast Asia has motivated systematic phytochemical investigation of its alkaloid content, of which girinimbine is among the most pharmacologically studied compounds to emerge.

Health Benefits

- **Anticancer Activity**: Girinimbine selectively inhibits proliferation of multiple cancer cell lines including A549 lung, HT-29 colon, and MCF7 breast cancer cells via intrinsic apoptotic pathway activation, with an IC₅₀ of approximately 19.01 μM in A549 cells, while sparing normal fibroblasts at equivalent concentrations.
- **Anti-inflammatory Effects**: At 51 ± 3.81 μg/mL, girinimbine inhibits nitric oxide production by 78.9% in LPS/IFN-γ-stimulated RAW 264.7 macrophages, and suppresses NF-κB nuclear translocation by up to 32.7% at 100 μg/mL, reducing downstream pro-inflammatory signaling cascades.
- **Anti-angiogenic Properties**: Girinimbine inhibits cancer cell invasion at 2.5–10 μg/mL in vitro and suppresses intersegmental vessel (ISV) formation in zebrafish embryo models at concentrations ≥20 μg/mL, suggesting potential for limiting tumor vascularization and metastatic spread.
- **Antioxidant Capacity**: At 20 μg/mL, girinimbine demonstrates antioxidant activity equivalent to 82.17 ± 1.88 μM Trolox in the ORAC (Oxygen Radical Absorbance Capacity) assay, indicating meaningful free radical scavenging potential relevant to oxidative stress-related pathologies.
- **Apoptosis Induction via Cell Cycle Arrest**: Girinimbine promotes G0/G1 phase cell cycle arrest in cancer cells with concurrent upregulation of cyclin-dependent kinase inhibitors p21 and p27 and tumor suppressor p53, mechanistically preventing uncontrolled cellular proliferation characteristic of malignant transformation.
- **Mitochondrial Membrane Disruption in Cancer Cells**: The compound disrupts mitochondrial membrane potential (MMP) in cancer cells, triggering cytochrome c release into the cytoplasm and subsequent caspase-9 and caspase-3 activation, committing cancer cells to programmed cell death while appearing non-toxic to normal cells.
- **Anti-nociceptive Potential**: Girinimbine's inhibition of pro-inflammatory mediators—including nitric oxide and NF-κB—suggests mechanistic plausibility for anti-nociceptive (pain-reducing) effects, consistent with its classification as an analgesic-modulating compound, though direct pain pathway studies in mammalian models remain limited.

How It Works

Girinimbine exerts its anticancer effects primarily through the intrinsic (mitochondrial) apoptotic pathway: it disrupts mitochondrial membrane potential, facilitating cytochrome c release into the cytosol, which activates the apoptosome and downstream caspase-9 and caspase-3 cleavage, ultimately inducing DNA fragmentation, chromatin condensation, and nuclear fragmentation characteristic of apoptosis. Simultaneously, it upregulates pro-apoptotic proteins including p21, p27, and p53 while downregulating anti-apoptotic Bcl-2, shifting the cellular balance toward cell death and enforcing G0/G1 cell cycle arrest. Anti-inflammatory activity is mediated through suppression of inducible nitric oxide synthase (iNOS)-driven NO overproduction and inhibition of NF-κB nuclear translocation, thereby reducing transcription of downstream inflammatory cytokines and pain-sensitizing mediators. Anti-angiogenic effects appear to target key angiogenesis-regulatory proteins governing endothelial cell invasion and new vessel sprouting, as evidenced by reduced intersegmental vessel formation in zebrafish embryo models at ≥20 μg/mL.

Scientific Research

All available evidence for girinimbine derives exclusively from preclinical research: in vitro cell-based assays using established cancer cell lines (HT-29, A549, MCF7, RAW 264.7 macrophages, CCD-18Co fibroblasts) and a limited in vivo zebrafish embryo angiogenesis model; no mammalian in vivo pharmacokinetic or efficacy studies and zero human clinical trials have been reported in the published literature. The in vitro studies quantify selective antiproliferative effects (IC₅₀ ≈ 19.01 μM in A549), anti-inflammatory potency (78.9% NO inhibition at 51 μg/mL), and antioxidant equivalence (82.17 μM Trolox at 20 μg/mL), providing mechanistically coherent but low-translational-confidence data. The zebrafish embryo model offers a modest in vivo dimension demonstrating anti-angiogenic activity at ≥20 μg/mL without embryo toxicity, but zebrafish pharmacology does not reliably predict human outcomes. Overall, the evidence base is preclinical-only, with no dose-response data in mammals, no bioavailability characterization, and no validated therapeutic window in humans, warranting extreme caution in extrapolating these findings to clinical or supplemental contexts.

Clinical Summary

There are currently no published human clinical trials investigating girinimbine for any indication, including cancer, inflammation, pain, or angiogenesis. All outcome data originates from in vitro experiments in cultured human and murine cell lines and a single zebrafish embryo in vivo model, representing the lowest tiers of translational evidence. Without pharmacokinetic profiling in mammals, oral bioavailability assessment, maximum tolerated dose studies, or Phase I safety trials, the therapeutic potential of girinimbine in humans cannot be quantified or confirmed. Confidence in girinimbine as a clinical agent is therefore very low at this time, and its promise in preclinical models—while scientifically interesting—should not be interpreted as evidence of human efficacy or safety.

Nutritional Profile

Girinimbine is a pure isolated alkaloid compound (molecular formula C₁₇H₁₇NO, molecular weight approximately 251.33 g/mol) and does not possess a conventional nutritional profile in terms of macronutrients, vitamins, or minerals. As a carbazole alkaloid, its biological relevance is entirely pharmacological rather than nutritive: it contributes no caloric value, dietary fiber, essential amino acids, or micronutrients. In the context of consuming whole Murraya koenigii leaves (the natural source), nutritional contributions include small amounts of carbohydrates, proteins, calcium, iron, and vitamins A, B, and C, along with a complex mixture of carbazole alkaloids (mahanimbine, mahanine, koenimbine, murrayanol), flavonoids, terpenoids, and essential oils—though girinimbine's specific concentration in fresh leaf material has not been precisely quantified in validated analytical studies. Bioavailability of girinimbine from whole plant consumption is unknown, as oral absorption, first-pass metabolism, plasma protein binding, and tissue distribution have not been characterized in any mammalian model.

Preparation & Dosage

- **Research-Grade Isolated Compound**: Girinimbine is prepared as a 10 mg/mL stock solution in DMSO for laboratory use, with final assay concentrations of 1.5–100 μg/mL (effective antiproliferative range approximately 10–25 μg/mL in cancer cell lines); DMSO concentration is maintained at ≤0.1% to avoid solvent cytotoxicity artifacts.
- **No Established Human Dose**: No standard supplemental dose, capsule, tablet, or extract form exists for human consumption; girinimbine is not approved or commercially available as a nutraceutical or pharmaceutical in any jurisdiction.
- **Traditional Plant Preparation (Murraya koenigii)**: The parent plant's leaves are consumed fresh, dried, or as decoctions in Ayurvedic and Southeast Asian culinary/medicinal traditions, but these preparations are not standardized for girinimbine content and deliver the alkaloid at undefined, likely low concentrations alongside hundreds of other phytochemicals.
- **Isolation Method**: Laboratory-grade girinimbine is isolated via solvent extraction of Murraya koenigii plant material (leaves, bark, or roots) followed by column chromatography and identity confirmation by NMR and mass spectrometry; no commercial standardized extract specifying girinimbine percentage is available on the market.
- **Timing and Form Notes**: Because no human pharmacokinetic data exist, appropriate dosing frequency, route of administration, and meal-timing guidance cannot be established; any future clinical development would require formal Phase I dose-escalation studies.

Synergy & Pairings

No formal synergy studies involving girinimbine in combination with other compounds have been published; however, its mechanistic profile—NF-κB inhibition and iNOS suppression—suggests potential additive or synergistic anti-inflammatory interactions with other NF-κB-targeting phytochemicals such as curcumin (from Curcuma longa) or resveratrol, which share overlapping signaling targets. In the context of anticancer activity, co-administration with agents that target the extrinsic apoptotic pathway (e.g., TRAIL-sensitizing compounds) may theoretically complement girinimbine's intrinsic mitochondrial pathway activation, though this remains entirely hypothetical without experimental validation. Stack combinations with other Murraya koenigii alkaloids (e.g., mahanine, mahanimbine) present a plausible area for synergy investigation given the plant's polypharmacological alkaloid mixture, but no combinatorial in vitro or in vivo data have been reported.

Safety & Interactions

In vitro safety data indicate that girinimbine does not induce significant cytotoxicity in normal human CCD-18Co fibroblasts or murine RAW 264.7 macrophages at concentrations up to 100 μg/mL over 24–48 hours, suggesting a degree of cancer cell selectivity; zebrafish embryo exposures at ≥20 μg/mL also produced no observable embryo toxicity. However, the absence of mammalian in vivo toxicology studies, including acute and chronic toxicity assessments, genotoxicity screening, reproductive toxicity evaluation, and organ-specific histopathology, means that a human safety profile cannot be constructed from existing data. No drug interactions have been studied or reported; given its mechanistic inhibition of NF-κB and apoptotic pathway modulation, theoretical interactions with immunosuppressants, chemotherapeutic agents, and anticoagulants cannot be excluded but remain entirely speculative. Girinimbine should not be self-administered by humans in isolated form, and its use during pregnancy or lactation cannot be assessed due to complete absence of reproductive safety data; all safety conclusions are extrapolated from cell-line data and should not be applied to clinical decision-making.